New drug combo shows promise for Tough-to-Treat throat cancer
NCT ID NCT03930498
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemotherapy can help people with a high-risk form of nasopharyngeal cancer that has come back. The trial involves 68 adults whose cancer returned at least a year after initial treatment and cannot be removed by surgery. Researchers are measuring survival, tumor response, side effects, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.